Neurosearch denies stock manipulation charge; Bavarian Nordic gets $32M to support PhIII;

 @FierceBiotech: Chasing a holy grail in pharma, Novo is confident that it can crack the blockbuster oral insulin market. More | Follow @FierceBiotech

 @JohnCFierce: Top biotechs boosted R&D spending 13% last year, and trend still points north. Special Report on biggest R&D spenders. More | Follow @JohnCFierce

 @RyanMFierce: Pfizer is offering heart-healthy recipes via a mobile app. The message: Eat well, take Lipitor. More | Follow @RyanMFierce

> Denmark's Neurosearch is denying charges that it manipulated its stock price. The charge is related to its initial press release on Phase III Huntexil data related to Huntington's disease. Story

> Bavarian Nordic says that an extra order by the U.S. government for $32 million worth of its smallpox vaccine will help support its late-stage study of the jab. Story

> Cambridge, MA-based Aveo ($AVEO) announced that it has launched a Phase I study of AV-203 along with exploratory biomarkers in patients with advanced solid tumors. Release

Pharma News

 @FiercePharma:  Counterfeit drugs threaten strides against malaria; Some companies trying text technology to combat fakes. More | Follow @FiercePharma

> Pfizer adds healthy-eating app to Lipitor marketing arsenal. More

> Merck CEO assures shareholders there is life after death of Singulair patent. News

> New use for Humira delayed as Abbott preps for spinoff. Article

Medical Devices News

 @FierceMedDev: Abiomed's share price dived 7% after an analyst downgraded the stock. He feared snafus over Impella's reimbursement. More | Follow @FierceMedDev

 @MarkHFierce: Please submit your nominations soon for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Healthsense, a crafter of wireless device monitors, seeks $13.7M. News

> Healthsense, a crafter of wireless device monitors, seeks $13.7M. Article

> In India, device companies will succeed by going local. Commentary

Drug Delivery News

 @DamianFierce: Prosonix says its new delivery platform makes combined APIs more effective: Story | Follow @DamianFierce

> New delivery method could help regenerate heart tissue. Article

> Impax cited by FDA in manufacturing inspection. Story

> Study: Boston Sci's drug-eluting stent safe, despite FDA warning. Item

Biomarkers News

> HDL isn't clear-cut biomarker, study suggests. News

> Gut microbe signature could tag radiation exposure. Story

> Blood test for bowel cancer is in the DNA. More

> Are you hungry? Biomarker spots preemies ready to feed. Article

And Finally… In a new study researchers conclude that bald men have a higher risk of prostate cancer. Release

 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.